Hims & Hers Q2 2026 slides: AI platform drives growth amid margin pressure

Hims & Hers Health (NYSE:HIMS) unveiled its Q2 2026 financials on August 10, 2026, illustrating a company's shift from telehealth provider to an AI-driven global consumer health platform. Despite a 40% year-over-year revenue increase to $753 million, the company posted a larger-than-anticipated loss of $0.37 per share, accompanied by declining gross margins and negative cash flow, reflecting the strain of expansion investments.

The platform attracted 2.9 million subscribers, a 19% year-over-year growth, with revenue per subscriber reaching $92 in Q2 2026. While domestic revenue grew by 16% to $622 million, international revenue surged to $131 million, a 17-fold increase year-over-year. Gross margins contracted to 64%, down approximately 6 percentage points sequentially, as branded weight-loss products and international operations generated lower margins compared to compounded offerings.

The AI-powered platform underwent a three-stage evolution, from convenient care access to data-driven personalization to AI-powered customer experiences. Management emphasized the platform's integration of AI across intake, treatment, and follow-up care, aiming to improve clinical efficiency. The company now operates across six specialties—Weight Loss, Sexual Health, Dermatology, Mental Health, Hormone Health, and Labs—in five regions serving over 600 million potential consumers.

The aggressive expansion strategy, fueled by acquisitions like Eucalyptus, is projected to unlock a massive addressable market opportunity, with management anticipating the Hers business to surpass $1 billion in annual revenue by 2026.